Interestingly, at the low E:T ratio of 0.5:1, only IL-2/IL-12/IL-18-pretreated γδ T cells exhibited a sustained anti-tumor effect, in fact irrespective of a simultaneous TCR stimulus (Figure 5). The gene discussed is IL18; the disease is neoplasm.